Abstract

Graves’ hyperthyroidism is caused by autoantibodies directed against the thyroid-stimulating hormone receptor (TSHR) that mimic the action of TSH. The establishment of Graves’ hyperthyroidism in experimental animals has proven to be an important approach to dissect the mechanisms of self-tolerance breakdown that lead to the production of thyroid-stimulating TSHR autoantibodies (TSAbs). “Shimojo’s model” was the first successful Graves’ animal model, wherein immunization with fibroblasts cells expressing TSHR and a major histocompatibility complex (MHC) class II molecule, but not either alone, induced TSAb production in AKR/N (H-2k) mice. This model highlights the importance of coincident MHC class II expression on TSHR-expressing cells in the development of Graves’ hyperthyroidism. These data are also in agreement with the observation that Graves’ thyrocytes often aberrantly express MHC class II antigens via mechanisms that remain unclear. Our group demonstrated that cytosolic self-genomic DNA fragments derived from sterile injured cells can induce aberrant MHC class II expression and production of multiple inflammatory cytokines and chemokines in thyrocytes in vitro, suggesting that severe cell injury may initiate immune responses in a way that is relevant to thyroid autoimmunity mediated by cytosolic DNA signaling. Furthermore, more recent successful Graves’ animal models were primarily established by immunizing mice with TSHR-expressing plasmids or adenovirus. In these models, double-stranded DNA vaccine contents presumably exert similar immune-activating effect in cells at inoculation sites and thus might pave the way toward successful Graves’ animal models. This review focuses on evidence suggesting that cell injury-derived self-DNA fragments could act as Graves’ disease triggers.

Highlights

  • Graves’ disease is a unique human autoimmune disease that involves stimulating autoantibodies directed toward thyroid-stimulating hormone receptors (TSHRs) on the surface of thyroid epithelial cells

  • Simultaneous major histocompatibility complex (MHC) class II expression was needed for TSHR autoantibodies (TSAbs) production and development of hyperthyroidism [27]. These results suggest that some genetic backgrounds are more susceptible to the induction of TSHR antibodies (TRAbs), while for the development of functional TRAbs, aberrant MHC class II expression is necessary

  • It is reasonable to speculate that muscle cells at the injection sites would express MHC class II and undergo adaptations to obtain some APC-like features after immunization with either plasmids or adenovirus

Read more

Summary

INTRODUCTION

Graves’ disease is a unique human autoimmune disease that involves stimulating autoantibodies directed toward thyroid-stimulating hormone receptors (TSHRs) on the surface of thyroid epithelial cells. Thyroid-stimulating hormone receptor endogenously expressed by vaccination is presumably presented preferentially through the MHC class I antigen pathway; the involvement of MHC class II presentation may be necessary for optimal T cell signaling during TSAb production, as implied in “Shimojo’s model.” To test this hypothesis, Pichurin et al constructed a chimeric plasmid that encodes TSHR and the lysosome-associated membrane protein (LAMP)-1, which has a sorting signal that can direct TSHR into lysosomes and, into the MHC class II presentation pathway. TSAbs persisted for more than 8 months after the final electroporation immunization [46], which is in contrast to the transient hyperthyroidism induced by intramuscular immunization wherein TSAb activity often began to decline much earlier or even completely disappeared [48] Another recently reported model of long-term Graves’ disease was established by prolonged intramuscular immunization with the ad-TSHR A subunit in female BALB/c mice [49]. Long-term Graves’ models would be useful for pharmacological analysis and for monitoring treatment response

CLASS II ON THYROCYTES
STIMULATED BY CYTOSOLIC DNA
CELL INJURY INDUCES APC ADAPTATION VIA CYTOSOLIC DNA SIGNALS
Findings
CONCLUSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.